Urteste S.A. enrolls the first patient in the Panuri test clinical study Gdansk, Poland - 10 June 2026 - Urteste S.A. (Warsaw Stock Exchange: URT), a company developing innovative technology for the ...
An interim report of a first-in-human phase 1 trial found an adjuvanted, combination inactivated rabies-vectored, Lassa fever vaccine (LASSARAB + 3D-6-acyl PHAD-SE) to be safe and induced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results